STAMFORD, Conn., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that management will participate in a fireside chat at Guggenheim’s Inaugural Healthcare Innovation Conference, taking place in Boston, Massachusetts on Wednesday, November 13, 2024 at 1:00 p.m. ET. To access the live webcast, please visit the Events & Presentations page within the Investors & Media section ...

Biotech Forum Discussion - The Biotech Forum has been dominated by discussions on lucrative buy-write or covered call opportunities on selected biotech stocks over the past several months [1] - The forum offers real-time trading ideas and insights from seasoned biotech investors [1] SpringWorks Therapeutics Overview - SpringWorks Therapeutics Inc (NASDAQ: SWTX) is now a "commercial" stage biotech firm focused on the development of medicines [2] - The company was last analyzed in-depth in July 2023 [2] Biotech Forum Services - The Biotech Forum provides a model portfolio featuring 12-20 high upside biotech stocks [2] - The forum offers live chat for discussing trade ideas, weekly research, and option trades [2] - Market commentary and portfolio updates are provided every weekend [2] Analyst Position - The analyst holds a beneficial long position in SWTX through stock ownership, options, or other derivatives [3]

STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates. To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by ph ...

A month has gone by since the last earnings report for SpringWorks Therapeutics (SWTX) . Shares have added about 11.7% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is SpringWorks Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers. SpringWorks Q2 Earnings B ...

SpringWorks Therapeutics (SWTX) closed the last trading session at $40.98, gaining 20.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66 indicates a 61.1% upside potential. The average comprises eight short-term price targets ranging from a low of $52 to a high of $77, with a standard deviation of $9.13. While the lowest estimate indicates an increase of 26.9% from the current ...

SpringWorks Therapeutics, Inc. (SWTX) announced that the FDA had accepted its new drug application ("NDA") seeking approval for the company's investigational MEK inhibitor, mirdametinib, which is being developed for the treatment of neurofibromatosis type 1- associated plexiform neurofibromas (NF1-PN), in pediatric and adult patients. With the FDA granting a priority review to the NDA, a decision from the regulatory body is expected on Feb. 28, 2025. At present, the FDA is not planning to hold an advisory c ...

– PDUFA target action date of February 28, 2025 – – EU Marketing Authorization Application also validated by European Medicines Agency – STAMFORD, Conn., Aug. 28, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company's New Drug Application (NDA) for mirdametinib, an investigational MEK inhibitor, for the treatment ...

SpringWorks Therapeutics' (SWTX) oral gamma-secretase inhibitor, Ogsiveo (nirogacestat), was approved by the FDA for treating adult patients with progressing desmoid tumors in November 2023. Following the FDA nod, not only Ogsiveo became the first approved product in the company's portfolio but it also became the first approved drug for treating desmoid tumors, a rare, aggressive tumor of the soft tissues. Ogsiveo has witnessed a strong initial uptake so far. The company's efforts to expand the drug's label ...

SpringWorks Therapeutics (SWTX) closed the last trading session at $36.96, gaining 0.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $65.75 indicates a 77.9% upside potential. The mean estimate comprises eight short-term price targets with a standard deviation of $8.81. While the lowest estimate of $52 indicates a 40.7% increase from the current price level, the most optimistic ...

SpringWorks Therapeutics, Inc. (SWTX) incurred a loss of 54 cents per share in the second quarter of 2024, which was significantly narrower than the Zacks Consensus Estimate of a loss of $1.12. The company had reported a loss of $1.25 per share in the year-ago quarter. In the second quarter, total revenues were $59.7 million, which also comprehensively beat the Zacks Consensus Estimate of $35 million. Total revenues comprised net product sales of Ogsiveo (nirogacestat) and other revenues. The company did no ...